Novo Nordisk registers two zenagamtide switch studies; IMPLEMENT HF recruitment continues

Two new Novo Nordisk Phase 1 studies join a continuing cardiology registry study this week.

• Novo Nordisk is recruiting for a Phase 1 study, "An Open-label, Multiple-arm Study to Assess Tolerability in Participants With Overweight or Obesity, With or Without Type 2 Diabetes, When Switching From Semaglutide to Zenagamtide" (NCT07855133), which aims to find out which zenagamtide dose can be switched to from a maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes.¹ The study has an actual start date of 2026-10-05 and plans to enroll 60 participants, with its primary outcome being the number of treatment emergent adverse events.¹
• Novo Nordisk is also recruiting for a parallel Phase 1 study, "An Open-label, Multiple-arm Study to Assess Tolerability in Participants With Overweight or Obesity, With or Without Type 2 Diabetes, When Switching From Tirzepatide to Zenagamtide" (NCT07868354), designed to find out which zenagamtide dose can be switched to from a maintenance dose of tirzepatide in people with overweight or obesity, with or without type 2 diabetes.² This study began 2026-10-08 and also plans to enroll 60 participants with the same primary outcome, tracking treatment emergent adverse events.²
• The IMPLEMENT HF registry study (NCT07702760), sponsored by Jasper Brugts MD PhD with the Dutch Heart Foundation as a collaborator, remains listed as recruiting. The study continues working toward its goal of enrolling 1,500 de novo HFrEF patients to show mirror information on four-pillar guideline-directed medical therapy prescription levels to treating physicians.³